- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07491107
Registo Prospectivo Brasileiro do Stent Farmacológico Inspiron EVO em Lesões Coronárias Complexas (PCI EVOlution)
Registo Prospectivo Nacional do Stent Farmacológico Inspiron EVO em Lesões Coronárias Complexas
The objective is to evaluate the efficacy and safety of the Inspiron™ EVO drug-eluting stent in complex coronary lesions in a real-world population. Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions will be treated with the Inspiron™ EVO drug-eluting stent.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Post-marketing, observational, prospective, multi-center, non-randomized, single-arm registry that will include all patients who receive the Inspiron™ EVO stent at participating sites and meet the eligibility criteria.
Up to 2,000 patients are expected to be enrolled across 12 research sites in Brazil. Participants' demographic, procedural, and follow-up data will be collected for up to 12 months in this study.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Marco Aurélio A Costa, MD, PhD
- Número de telefone: +1 216 903-9327
- E-mail: marco.costa@scitechmed.com
Estude backup de contato
- Nome: Ana Paula B Pellaquim, MSc.
- Número de telefone: +55 62 9471-4439
- E-mail: aalmeida@scitechmed.com
Locais de estudo
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasil, 90610000
- Recrutamento
- Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
-
Contato:
- Paulo Ricardo A Caramori, MD
- Número de telefone: +55 51 99982 0766
- E-mail: caramori@cardiarte.com.br
-
Contato:
- Rosa Homem
- Número de telefone: +55 51 99679 8040
- E-mail: cer.pesquisaclinica@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Patients with symptomatic ischemic heart disease due to lesions in native coronary arteries and restenotic lesions treated with the Inspiron™ EVO Drug-Eluting Stent.
Descrição
Inclusion Criteria:
- Individuals aged 18 years or older presenting with complex coronary lesions requiring percutaneous coronary intervention (PCI).
- Individuals who provide consent and are willing to comply with the follow-up protocol.
- Individuals who received treatment with the Inspiron™ EVO Stent.
- Individuals with lesions ≥ 30 mm in length (Subprotocol 1).
- Individuals with significantly calcified coronary lesions (moderate to severe according to the ACC/AHA classification B1, B2, or C), with or without indication for lesion preparation techniques (Subprotocol 2).
- Individuals with multivessel coronary artery disease (≥2 affected coronary vessels, with at least one vessel of small diameter ≤2.5 mm) (Subprotocol 3).
- Individuals included in Subprotocol 1, 2, or 3. The evaluated segment must be accessible to the IVUS (Intravascular Ultrasound) catheter (Subprotocol 4).
Exclusion Criteria:
- Lesions in saphenous vein grafts or internal mammary grafts.
- Contraindication to the use of a drug-eluting stent.
- Individuals who were treated during the index procedure with any stent other than the Inspiron™ EVO Stent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Experimental: Percutaneous coronary intervention (PCI)
Patients with symptomatic ischemic heart disease due to lesions in the native coronary artery and restenotic lesions treated with the Inspiron™ EVO drug-eluting stent. |
Percutaneous coronary intervention (PCI) using the Inspiron EVO Drug-Eluting Stent, which has a reduced crimped profile, providing greater safety and facilitating lesion crossing. In addition, the design is optimized to provide increased radial strength. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Device success
Prazo: Initial procedure
|
Device success (at the lesion level) is defined as the successful delivery, balloon expansion, and implantation of the first device at the target lesion (with multiple attempts using the same device permitted), successful withdrawal of the delivery system, and achievement of a final in-stent residual stenosis of <20% |
Initial procedure
|
|
Acute Clinical Success of Percutaneous Coronary Intervention (PCI)
Prazo: Up to 24 hours
|
Defined as the absence of major adverse in-hospital cardiac events (death, myocardial infarction, or repeat coronary revascularization of the target lesion). |
Up to 24 hours
|
|
MACE (Major Adverse Cardiac Events) rate
Prazo: 12 months
|
Defined as the combination of cardiac death, myocardial infarction (MI), or revascularization of the target lesion (TLR). |
12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Target Lesion Revascularization (TLR) rate
Prazo: 12 months
|
TLR is defined as any percutaneous reintervention of the target lesion, including the 5 mm proximal and 5 mm distal segments of the stent, or revascularization of the target vessel, performed for clinical reasons due to restenosis or occlusion of the target lesion. |
12 months
|
|
Target vessel revascularization rate (TVR)
Prazo: 12 months
|
TVR is defined as revascularization of any segment of the target coronary artery. |
12 months
|
|
Target Vessel Failure Rate (TVF)
Prazo: 12 months
|
Defined as a combination of MI, TLR, or cardiovascular death related to the target vessel. If it is not possible to determine with certainty whether the MI or death was related to the target vessel, the case is considered a TVF. |
12 months
|
|
Rate of definite, probable, and possible stent thrombosis (ST)
Prazo: 12 months
|
Stent thrombosis is classified as definite, probable, or possible: definite requires angiographic or pathological confirmation; probable includes unexplained death within 30 days or myocardial infarction related to the stented territory without angiographic confirmation; and possible refers to any unexplained death occurring from 30 days after implantation until the end of follow-up. |
12 months
|
|
Cardiovascular mortality
Prazo: 12 months
|
Any death due to an immediate cardiac cause (e.g., myocardial infarction, low-output heart failure, fatal arrhythmia), unwitnessed death, death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death. |
12 months
|
|
Late in-segment luminal loss (including the in-stent portion and the 5-mm proximal and distal edges)
Prazo: 6 months
|
Defined as the difference between the in-segment minimum luminal diameter (MLD) (including the in-stent portion and the 5-mm proximal and distal edges) after the procedure and the MLD at the 6-month follow-up, as determined by quantitative angiography. |
6 months
|
|
Percent Area Stenosis (%AS)
Prazo: 6 months
|
Defined as the ratio between the neointimal hyperplasia area and the stent area multiplied by 100 at the 6-month follow-up. |
6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Paulo Ricardo A Caramori, MD, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS)
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SCI-EV-001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .